Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome

Trial Profile

A Phase 2, Open Label, Multicenter Study of ALN-CC5 Administered Subcutaneously in Adult Patients with Atypical Hemolytic Uremic Syndrome

Discontinued
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2018

At a glance

  • Drugs Cemdisiran (Primary)
  • Indications Atypical Haemolytic Uraemic Syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Alnylam Pharmaceuticals
  • Most Recent Events

    • 10 Nov 2018 This trial was Completed in Estonia (end date: 2018-09-12), according to European Clinical Trials Database.
    • 03 Oct 2018 This trial was Completed in Sweden (end date: 2018-09-12), according to European Clinical Trials Database.
    • 26 Sep 2018 This trial was completed in Latvia (end date: 2018-09-12), according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top